Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Nov;96(5):2331–2338. doi: 10.1172/JCI118289

Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats.

V Shen 1, R Birchman 1, R Xu 1, M Otter 1, D Wu 1, R Lindsay 1, D W Dempster 1
PMCID: PMC185884  PMID: 7593620

Abstract

Intermittent administration of PTH has been found to be an effective anabolic agent in cancellous bone. We have reported previously that combined treatment with PTH and estrogen in estrogen-deficient rats was beneficial in correcting established osteopenia. To determine if the beneficial effects of PTH therapy can be preserved by estrogen alone and whether PTH therapy can be effective in treating osteopenic subjects stabilized with estrogen, we have undertaken a "crossover" study in the rat model of estrogen-deficiency induced osteopenia. Six-month-old female rats were ovariectomized and after 5 wk treated for 8 wk with vehicle, 30 micrograms/kg per day of rPTH(1-34) plus 15 micrograms/kg per day of 17 beta-estradiol or 17 beta-estradiol alone. One group from each treatment regimen was then sacrificed and for an additional 8 weeks the remaining rats were (a) maintained on their previous treatment; (b) "crossed over" to their reciprocal treatment; or (c) administered vehicle only. At the end of this second 8-wk treatment period all rats were sacrificed. Bone mineral density of the distal femur, histomorphometric measurements of the proximal tibia and mechanical testing of the distal femur and selected vertebral bodies were performed. Our results demonstrated that (a) the gains in bone mass, trabecular connectivity and mechanical strength induced by PTH can be maintained by estrogen alone, but are reversed when both agents are withdrawn; and (b) rats with established osteopenia, maintained on estrogen treatment alone, can derive the full beneficial effects from the addition of PTH to the treatment at a later date. These data indicate that combined and/or sequential use of antiresorptive and anabolic agents may be a promising approach to the treatment of osteoporosis.

Full text

PDF
2331

Images in this article

2332Image
on p.2332

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aerssens J., Van Audekercke R., Geusens P., Schot L. P., Osman A. A., Dequeker J. Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment. Calcif Tissue Int. 1993 Oct;53(4):269–277. doi: 10.1007/BF01320913. [DOI] [PubMed] [Google Scholar]
  2. Akamine T., Jee W. S., Ke H. Z., Li X. J., Lin B. Y. Prostaglandin E2 prevents bone loss and adds extra bone to immobilized distal femoral metaphysis in female rats. Bone. 1992;13(1):11–22. doi: 10.1016/8756-3282(92)90356-2. [DOI] [PubMed] [Google Scholar]
  3. Ammann P., Rizzoli R., Müller K., Slosman D., Bonjour J. P. IGF-I and pamidronate increase bone mineral density in ovariectomized adult rats. Am J Physiol. 1993 Nov;265(5 Pt 1):E770–E776. doi: 10.1152/ajpendo.1993.265.5.E770. [DOI] [PubMed] [Google Scholar]
  4. Bagi C. M., Brommage R., Deleon L., Adams S., Rosen D., Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res. 1994 Aug;9(8):1301–1312. doi: 10.1002/jbmr.5650090820. [DOI] [PubMed] [Google Scholar]
  5. Bradbeer J. N., Arlot M. E., Meunier P. J., Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 1992 Sep;37(3):282–289. doi: 10.1111/j.1365-2265.1992.tb02323.x. [DOI] [PubMed] [Google Scholar]
  6. Cheng P. T., Chan C., Müller K. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate. J Bone Miner Res. 1995 Jan;10(1):119–126. doi: 10.1002/jbmr.5650100117. [DOI] [PubMed] [Google Scholar]
  7. Christiansen C. Prevention and treatment of osteoporosis: a review of current modalities. Bone. 1992;13 (Suppl 1):S35–S39. doi: 10.1016/s8756-3282(09)80008-2. [DOI] [PubMed] [Google Scholar]
  8. Cody D. D., Goldstein S. A., Flynn M. J., Brown E. B. Correlations between vertebral regional bone mineral density (rBMD) and whole bone fracture load. Spine (Phila Pa 1976) 1991 Feb;16(2):146–154. [PubMed] [Google Scholar]
  9. Ejersted C., Andreassen T. T., Oxlund H., Jørgensen P. H., Bak B., Häggblad J., Tørring O., Nilsson M. H. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res. 1993 Sep;8(9):1097–1101. doi: 10.1002/jbmr.5650080910. [DOI] [PubMed] [Google Scholar]
  10. Garrahan N. J., Mellish R. W., Compston J. E. A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J Microsc. 1986 Jun;142(Pt 3):341–349. doi: 10.1111/j.1365-2818.1986.tb04289.x. [DOI] [PubMed] [Google Scholar]
  11. Gunness-Hey M., Hock J. M. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Relat Res. 1984;5(4):177–181. doi: 10.1016/0221-8747(84)90026-2. [DOI] [PubMed] [Google Scholar]
  12. Gunness-Hey M., Hock J. M. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone. 1989;10(6):447–452. doi: 10.1016/8756-3282(89)90077-x. [DOI] [PubMed] [Google Scholar]
  13. Hesch R. D., Busch U., Prokop M., Delling G., Rittinghaus E. F. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int. 1989 Mar;44(3):176–180. doi: 10.1007/BF02556561. [DOI] [PubMed] [Google Scholar]
  14. Hock J. M., Gera I., Fonseca J., Raisz L. G. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology. 1988 Jun;122(6):2899–2904. doi: 10.1210/endo-122-6-2899. [DOI] [PubMed] [Google Scholar]
  15. Hvid I., Andersen K., Olesen S. Cancellous bone strength measurements with the osteopenetrometer. Eng Med. 1984 Apr;13(2):73–78. doi: 10.1243/emed_jour_1984_013_019_02. [DOI] [PubMed] [Google Scholar]
  16. Hvid I., Hansen S. L. Trabecular bone strength patterns at the proximal tibial epiphysis. J Orthop Res. 1985;3(4):464–472. doi: 10.1002/jor.1100030409. [DOI] [PubMed] [Google Scholar]
  17. Ibbotson K. J., Orcutt C. M., D'Souza S. M., Paddock C. L., Arthur J. A., Jankowsky M. L., Boyce R. W. Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis. J Bone Miner Res. 1992 Apr;7(4):425–432. doi: 10.1002/jbmr.5650070410. [DOI] [PubMed] [Google Scholar]
  18. Jee W. S., Mori S., Li X. J., Chan S. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone. 1990;11(4):253–266. doi: 10.1016/8756-3282(90)90078-d. [DOI] [PubMed] [Google Scholar]
  19. Jee W. S., Tang L., Ke H. Z., Setterberg R. B., Kimmel D. B. Maintaining restored bone with bisphosphonate in the ovariectomized rat skeleton: dynamic histomorphometry of changes in bone mass. Bone. 1993 May-Jun;14(3):493–498. doi: 10.1016/8756-3282(93)90185-d. [DOI] [PubMed] [Google Scholar]
  20. Kalu D. N., Echon R., Hollis B. W. Modulation of ovariectomy-related bone loss by parathyroid hormone in rats. Mech Ageing Dev. 1990 Oct;56(1):49–62. doi: 10.1016/0047-6374(90)90114-u. [DOI] [PubMed] [Google Scholar]
  21. Kalu D. N., Salerno E., Higami Y., Liu C. C., Ferraro F., Salih M. A., Arjmandi B. H. In vivo effects of transforming growth factor-beta 2 in ovariectomized rats. Bone Miner. 1993 Sep;22(3):209–220. doi: 10.1016/s0169-6009(08)80069-4. [DOI] [PubMed] [Google Scholar]
  22. Katsumata T., Nakamura T., Ohnishi H., Sakurama T. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res. 1995 Jun;10(6):921–931. doi: 10.1002/jbmr.5650100613. [DOI] [PubMed] [Google Scholar]
  23. Ke H. Z., Li X. J., Jee W. S. Partial loss of anabolic effect of prostaglandin E2 on bone after its withdrawal in rats. Bone. 1991;12(3):173–183. doi: 10.1016/8756-3282(91)90040-p. [DOI] [PubMed] [Google Scholar]
  24. Kleerekoper M., Peterson E. L., Nelson D. A., Phillips E., Schork M. A., Tilley B. C., Parfitt A. M. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991 Jun;1(3):155–161. doi: 10.1007/BF01625446. [DOI] [PubMed] [Google Scholar]
  25. Liu C. C., Kalu D. N. Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res. 1990 Sep;5(9):973–982. doi: 10.1002/jbmr.5650050911. [DOI] [PubMed] [Google Scholar]
  26. Liu C. C., Kalu D. N., Salerno E., Echon R., Hollis B. W., Ray M. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res. 1991 Oct;6(10):1071–1080. doi: 10.1002/jbmr.5650061008. [DOI] [PubMed] [Google Scholar]
  27. Martin R. B. Effects of simulated weightlessness on bone properties in rats. J Biomech. 1990;23(10):1021–1029. doi: 10.1016/0021-9290(90)90317-v. [DOI] [PubMed] [Google Scholar]
  28. Mellish R. W., Ferguson-Pell M. W., Cochran G. V., Lindsay R., Dempster D. W. A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. J Bone Miner Res. 1991 Jul;6(7):689–696. doi: 10.1002/jbmr.5650060706. [DOI] [PubMed] [Google Scholar]
  29. Mitlak B. H., Williams D. C., Bryant H. U., Paul D. C., Neer R. M. Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J Bone Miner Res. 1992 May;7(5):479–484. doi: 10.1002/jbmr.5650070503. [DOI] [PubMed] [Google Scholar]
  30. Mosekilde L., Danielsen C. C., Gasser J. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology. 1994 May;134(5):2126–2134. doi: 10.1210/endo.134.5.8156913. [DOI] [PubMed] [Google Scholar]
  31. Mosekilde L., Danielsen C. C., Knudsen U. B. The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone. 1993;14(1):1–6. doi: 10.1016/8756-3282(93)90248-9. [DOI] [PubMed] [Google Scholar]
  32. Mosekilde L., Søgaard C. H., McOsker J. E., Wronski T. J. PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate)--assessed in sexually mature, ovariectomized rats. Bone. 1994 Jul-Aug;15(4):401–408. doi: 10.1016/8756-3282(94)90816-8. [DOI] [PubMed] [Google Scholar]
  33. Mosekilde L. Vertebral structure and strength in vivo and in vitro. Calcif Tissue Int. 1993;53 (Suppl 1):S121–S126. doi: 10.1007/BF01673420. [DOI] [PubMed] [Google Scholar]
  34. Mueller K., Cortesi R., Modrowski D., Marie P. J. Stimulation of trabecular bone formation by insulin-like growth factor I in adult ovariectomized rats. Am J Physiol. 1994 Jul;267(1 Pt 1):E1–E6. doi: 10.1152/ajpendo.1994.267.1.E1. [DOI] [PubMed] [Google Scholar]
  35. Oxlund H., Ejersted C., Andreassen T. T., Tørring O., Nilsson M. H. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int. 1993 Dec;53(6):394–399. [PubMed] [Google Scholar]
  36. Parfitt A. M., Mathews C. H., Villanueva A. R., Kleerekoper M., Frame B., Rao D. S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 1983 Oct;72(4):1396–1409. doi: 10.1172/JCI111096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Reeve J., Meunier P. J., Parsons J. A., Bernat M., Bijvoet O. L., Courpron P., Edouard C., Klenerman L., Neer R. M., Renier J. C. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980 Jun 7;280(6228):1340–1344. doi: 10.1136/bmj.280.6228.1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Riggs B. L., Seeman E., Hodgson S. F., Taves D. R., O'Fallon W. M. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med. 1982 Feb 25;306(8):446–450. doi: 10.1056/NEJM198202253060802. [DOI] [PubMed] [Google Scholar]
  39. Rosen D., Miller S. C., DeLeon E., Thompson A. Y., Bentz H., Mathews M., Adams S. Systemic administration of recombinant transforming growth factor beta 2 (rTGF-beta 2) stimulates parameters of cancellous bone formation in juvenile and adult rats. Bone. 1994 May-Jun;15(3):355–359. doi: 10.1016/8756-3282(94)90300-x. [DOI] [PubMed] [Google Scholar]
  40. Shen V., Dempster D. W., Birchman R., Xu R., Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest. 1993 Jun;91(6):2479–2487. doi: 10.1172/JCI116483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Spencer E. M., Liu C. C., Si E. C., Howard G. A. In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone. 1991;12(1):21–26. doi: 10.1016/8756-3282(91)90050-s. [DOI] [PubMed] [Google Scholar]
  42. Stepán J. J., Pospíchal J., Presl J., Pacovský V. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone. 1987;8(5):279–284. doi: 10.1016/8756-3282(87)90002-0. [DOI] [PubMed] [Google Scholar]
  43. Søgaard C. H., Wronski T. J., McOsker J. E., Mosekilde L. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology. 1994 Feb;134(2):650–657. doi: 10.1210/endo.134.2.8299562. [DOI] [PubMed] [Google Scholar]
  44. Tang L. Y., Jee W. S., Ke H. Z., Kimmel D. B. Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure. J Bone Miner Res. 1992 Sep;7(9):1093–1104. doi: 10.1002/jbmr.5650070913. [DOI] [PubMed] [Google Scholar]
  45. Tobias J. H., Chow J. W., Chambers T. J. Opposite effects of insulin-like growth factor-I on the formation of trabecular and cortical bone in adult female rats. Endocrinology. 1992 Nov;131(5):2387–2392. doi: 10.1210/endo.131.5.1425437. [DOI] [PubMed] [Google Scholar]
  46. Turner C. H., Burr D. B. Basic biomechanical measurements of bone: a tutorial. Bone. 1993 Jul-Aug;14(4):595–608. doi: 10.1016/8756-3282(93)90081-k. [DOI] [PubMed] [Google Scholar]
  47. Wronski T. J., Cintrón M., Dann L. M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int. 1988 Sep;43(3):179–183. doi: 10.1007/BF02571317. [DOI] [PubMed] [Google Scholar]
  48. Wronski T. J., Yen C. F. Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone. 1994 Jan-Feb;15(1):51–58. doi: 10.1016/8756-3282(94)90891-5. [DOI] [PubMed] [Google Scholar]
  49. Wronski T. J., Yen C. F., Qi H., Dann L. M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 1993 Feb;132(2):823–831. doi: 10.1210/endo.132.2.8425497. [DOI] [PubMed] [Google Scholar]
  50. Yamamoto N., Takahashi H. E., Tanizawa T., Fujimoto R., Hara T., Tanaka S. Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH(1-34) administration. Bone Miner. 1993 Dec;23(3):333–342. doi: 10.1016/s0169-6009(08)80107-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES